SCHEMBL1217899

SCHEMBL1217899

COC(=O)c1nn(Cc2ccc(C#N)cc2)c2c(F)cccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.46
CYP11B2 P19099 3/20 0.46
SLC2A1 P11166 3/20 0.42
SLC2A3 P11169 3/20 0.42
SLC2A4 P14672 3/20 0.42
SLC2A2 P11168 1/20 0.42
AR P10275 1/20 0.42
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
ELANE P08246 1/20 0.40
USP14 P54578 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ABCB1 P08183 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90B1 P14625 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1218252 0.87 SLC2A1 (0.41) CYP11B1CYP11B2SLC2A1SLC2A3SLC2A4
SCHEMBL12898733 0.79 CYP11B1 (0.42) CYP11B1CYP11B2SLC2A1SLC2A3SLC2A4
SCHEMBL1218423 0.79 CNR1 (0.49) SLC2A1SLC2A3SLC2A4SLC2A2ABCB1
SCHEMBL1217759 0.77 SLC2A1 (0.41) SLC2A1SLC2A3SLC2A4SLC2A2ALDH1A1
SCHEMBL12885092 0.77 SLC2A1 (0.41) SLC2A1SLC2A3SLC2A4SLC2A2ALDH1A1
SCHEMBL1215113 0.76 SLC2A1 (0.40) SLC2A1SLC2A3SLC2A4SLC2A2ALDH1A1
SCHEMBL1218578 0.76 SLC2A1 (0.43) SLC2A1SLC2A3SLC2A4SLC2A2ABCB1
SCHEMBL12885580 0.76 MEN1 (0.42) SLC2A1SLC2A3SLC2A4SLC2A2ABCB1
SCHEMBL1218838 0.75 PRKAA2 (0.41) SLC2A1SLC2A3SLC2A4SLC2A2ABCB1
SCHEMBL12885326 0.75 FPR1 (0.42) SLC2A1SLC2A3SLC2A4SLC2A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028447-A1 INDAZOLE DERIVATIVES PFIZER INC. 2011-02-03 US disclosed
US-20110028447-A1 INDAZOLE DERIVATIVES PFIZER INC. 2011-02-03 US disclosed
EP-2265335-A1 INDAZOLE DERIVATIVES Pfizer Inc. (US) 2010-12-29 EP disclosed
WO-2009106982-A1 INDAZOLE DERIVATIVES PFIZER INC. (US) 2009-09-03 WO disclosed
WO-2009106982-A1 INDAZOLE DERIVATIVES PFIZER INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028447-A1 INDAZOLE DERIVATIVES CNR1, CNR2, GPR119 CYP11B1 149/4885CYP11B2 132/4885SLC2A1 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.